Jenburkt Pharmaceuticals shareholding pattern

JENBURPH

1028

5.40 (-0.52%)
Last updated on 20 Feb, 2026 | 15:29 IST
alert_iconwatchlist_icon
BUYSELL
Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Jenburkt Pharmaceuticals Shareholding Pattern

  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

46.65%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

0%

Domestic Institutional Investors

0.12%

Retail

53.24%

Others

-0.01%

Total Promoters
MAR '25
46.68%
JUN '25
46.67%
SEP '25
46.66%
DEC '25
46.65%

Summary

For Year 2025-26, Jenburkt Pharmaceuticals reports the following shareholding: Total Promoters at 46.65%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 0.12%, and Retail at 53.24%. This breakdown provides a quick snapshot of ownership distribution for Jenburkt Pharmaceuticals in 2025-26.

Jenburkt Pharmaceuticals FAQs

As of 02-2026, the promoter shareholding in Jenburkt Pharmaceuticals stands at 46.65% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Jenburkt Pharmaceuticals is 0% and 0.12% respectively.

The retail shareholding of the Jenburkt Pharmaceuticals is 53.24%.

Changes in shareholding patterns of Jenburkt Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Jenburkt Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost